Stoke Therapeutics (STOK) Accounts Payables (2018 - 2026)

Stoke Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 212.85% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 212.85% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 97.72% from the prior year.
• Accounts Payables rose to $6.8 million in Q1 2026 per STOK's latest filing, from $4.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $6.8 million in Q1 2026 and bottomed at $766000.0 in Q4 2022.
• The 5-year median for Accounts Payables is $3.1 million (2023), against an average of $3.3 million.
• Biggest YoY gain for Accounts Payables was 274.04% in 2022; the steepest drop was 67.88% in 2022.
• Year by year, Accounts Payables stood at $766000.0 in 2022, then soared by 121.28% to $1.7 million in 2023, then soared by 47.37% to $2.5 million in 2024, then jumped by 97.72% to $4.9 million in 2025, then soared by 38.47% to $6.8 million in 2026.
• Per Business Quant, the three latest STOK Accounts Payables figures stand at $6.8 million (Q1 2026), $4.9 million (Q4 2025), and $5.9 million (Q3 2025).